Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world observational study of insulin glargine + lixisenatide after switch from basal insulin in adults with type 2 diabetes mellitus
NL-OMON24198Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jan 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoint: Mean change in HbA1c from baseline to week 24. Started Jan 2020; status: active, not recruiting.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON24198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24198.